ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of ...

Czech Deputy Health Minister Michaela Matoušková urges the EU to take stronger, proactive steps on pharmaceutical policy, digital health coordination, and equitable access to innovative medicines.

The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The ...

Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...

A new review published in JAMA Network Open describes how often ethics are incorporated in infectious diseases international ...

Uncoordinated price cuts across the EU are contributing to medicine shortages and driving manufacturers towards more ...

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE ...

NHS England » NHS to roll-out new ‘triple combination’ therapy for hundreds of children and adults with cystic fibrosis ...

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and broaden its product portfolio. To build its long-term portfolio, the company ...

France, Spain, Italy, Denmark and Greece will test a blueprint for an age verification app to protect children online, the European Commission said on Monday, amid growing global concern about the ...

The amended product information will provide more specific detail on encephalitis as a known adverse reaction to ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa ...